NBRVF (Nabriva Therapeutics) FCF Margin %: 19.85% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NBRVF Nabriva Therapeutics PLC NBRVF
12 GF Score
Price $0.00
View Full Analysis

What is Nabriva Therapeutics FCF Margin %?

Nabriva Therapeutics NBRVF 12 FCF Margin % is 19.85% as of Jun. 2023. GuruFocus rates NBRVF with a GF Score™ of 12/100.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nabriva Therapeutics's Free Cash Flow for the three months ended in Jun. 2023 was $0.51 Mil. Nabriva Therapeutics's Revenue for the three months ended in Jun. 2023 was $2.57 Mil. Therefore, Nabriva Therapeutics's FCF Margin % for the quarter that ended in Jun. 2023 was 19.85%.

As of today, Nabriva Therapeutics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Nabriva Therapeutics's FCF Margin % or its related term are showing as below:

NBRVF' s FCF Margin % Range Over the Past 10 Years
Min: -44.32   Med: 0   Max: 0
Current: -44.32

NBRVF's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -81.28 vs NBRVF: -44.32

Nabriva Therapeutics FCF Margin % Related Terms

Nabriva Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Nabriva Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nabriva Therapeutics FCF Margin % Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,122.34 -928.67 -2,494.55 -218.92 -103.52

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -149.30 -71.49 -15.65 -74.06 19.85

NBRVF vs BXRX, INM, ADTX: FCF Margin % Comparison

For the Biotechnology subindustry, Nabriva Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's FCF Margin % falls into.


NBRVF
12GF Score
Nabriva Therapeutics PLC NBRVF
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nabriva Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nabriva Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-36.922/35.668
=-103.52 %

Nabriva Therapeutics's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=0.511/2.574
=19.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 19.85% mean?
Nabriva Therapeutics (NBRVF) has a FCF Margin % of 19.85% as of Jun. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nabriva Therapeutics and its competitors.
Is Nabriva Therapeutics' FCF Margin % too high?
Nabriva Therapeutics' current FCF Margin % is 19.85%. Overall, Nabriva Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nabriva Therapeutics' FCF Margin % compare to BXRX and INM?
Nabriva Therapeutics' FCF Margin % of 19.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nabriva Therapeutics and its competitors. Nabriva Therapeutics's current FCF Margin % is 19.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nabriva Therapeutics stock overvalued right now?
Nabriva Therapeutics (NBRVF) has a current FCF Margin % of 19.85%. The current FCF Margin % is 19.85%. Nabriva Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nabriva Therapeutics (NBRVF), the current FCF Margin % is 19.85% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nabriva Therapeutics Business Description

Address Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
12GF Score

Get the complete analysis for NBRVF

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price